| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,063,572 | 6 | 100 |
| Hanson Kristopher | General Counsel | 0 | $0 | 1 | $72,882 | $-72,882 |
| GILLIS JONATHAN | CAO and Interim CFO | 0 | $0 | 1 | $82,149 | $-82,149 |
| Lillie James Woodruff | Chief Scientific Officer | 0 | $0 | 1 | $93,025 | $-93,025 |
| Kreitzer Anatol | Chief Discovery Officer | 0 | $0 | 1 | $96,024 | $-96,024 |
| Foff Erin Pennock | Chief Medical Officer | 0 | $0 | 1 | $124,068 | $-124,068 |
| Kroeger Christopher A. | Chief Executive Officer | 0 | $0 | 1 | $595,423 | $-595,423 |
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability …
Over the last 12 months, insiders at MapLight Therapeutics, Inc. have bought $0 and sold $1.06M worth of MapLight Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at MapLight Therapeutics, Inc. have bought $0 and sold $1.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-15 | Sale | Kroeger Christopher A. | Chief Executive Officer | 73,691 0.1742% | $8.08 | $595,423 | -0.62% | |
| 2026-10-15 | Sale | Foff Erin Pennock | Chief Medical Officer | 15,355 0.0363% | $8.08 | $124,068 | -0.62% | |
| 2026-10-15 | Sale | Lillie James Woodruff | Chief Scientific Officer | 11,513 0.0272% | $8.08 | $93,025 | -0.62% | |
| 2026-10-15 | Sale | Kreitzer Anatol | Chief Discovery Officer | 12,248 0.0281% | $7.84 | $96,024 | -0.62% | |
| 2026-10-15 | Sale | GILLIS JONATHAN | CAO and Interim CFO | 10,167 0.024% | $8.08 | $82,149 | -0.62% | |
| 2026-10-15 | Sale | Hanson Kristopher | General Counsel | 9,020 0.0213% | $8.08 | $72,882 | -0.62% |
| Increased Positions | 73 | 0% | 23M | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 73 | New | 23M | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 73 | 0% | 23M | 0% |